With a short percentage of shares outstanding of 0.24%, Novartis AG (NYSE:NVS) is among the 7 Best Longevity and Anti-Aging Stocks to Buy
On June 12, Novartis AG (NYSE:NVS) presented results from the RemIND trial at the European Academy of Allergy and Clinical Immunology Congress, demonstrating that Rhapsido achieved its primary endpoints across the three most common chronic inducible urticaria subtypes. The therapy became the first treatment to show efficacy in a global Phase III clinical trial for chronic inducible urticaria, with higher rates of complete responses observed by week 12 and clinical benefits emerging as early as week 2 in two of the subtypes. The findings suggest that Rhapsido may offer durable symptom relief for patients whose condition remains inadequately controlled despite treatment with second-generation H1-antihistamines.
On June 10, Novartis AG (NYSE:NVS) announced a multi-year collaboration with Orionis Biosciences to discover and develop molecular glue therapeutics targeting challenging disease pathways across multiple therapeutic areas. The agreement expands the companies’ existing relationship and will combine Orionis’ Allo-Glue platform and AI-driven discovery capabilities with Novartis’ drug development expertise to accelerate target identification, ligase profiling, and molecular glue optimization. Under the terms of the collaboration, Orionis will receive a $40 million upfront payment and may earn up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales.
Incorporated in March 1996 and headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) is a multinational pharmaceutical corporation that researches and develops innovative prescription medicines. The company explores the mTOR pathway class of compounds, aiming to delay age-related diseases and extend health span
While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock
READ NEXT:10 Most Overvalued Quantum Computing Stocks According to Short Sellers and7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue
Disclosure: None. Follow Insider Monkey on Google News
